Klaria Interim Report

Klaria Pharma AB - Interim Report Q3 2019

Initiated large-scale production of KL-00119 oral film (sumatriptan) for upcoming registration study

THIRD QUARTER OF 2019

∞ Net sales amounted to 0.1 MSEK (0.0 MSEK)

∞ R&D costs for the period amounted to 5.4 MSEK (4.6 MSEK)

∞ Profit after tax amounted to -7.2 MSEK (-6.1 MSEK)

∞ Earnings per share for the quarter amounted to -0.23 SEK (-0.20 SEK)

∞ Cash flow from operating activities amounted to -5.5 MSEK (-3.2 MSEK)

∞ Cash and cash equivalents on the balance day amounted to 8.9 MSEK (5.1 MSEK)

∞ Shareholder’s equity per September 30, 2019 amounted to 87.5 MSEK (102.8 MSEK)

For more information, visit the Klaria Pharma Holding website klaria.com or contact:
Scott Boyer, CEO Klaria Pharma Holding AB (publ)
scott.boyer@klaria.com
Tel: +46 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.